{"id":913483,"date":"2025-11-25T07:35:53","date_gmt":"2025-11-25T12:35:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/"},"modified":"2025-11-25T07:35:53","modified_gmt":"2025-11-25T12:35:53","slug":"briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/","title":{"rendered":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>The pivotal Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>The Bria-IMT regimen has received Fast Track Designation from US FDA<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Nov.  25, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS<sup>\u00ae<\/sup>) taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.<\/p>\n<p align=\"justify\">\u201cPositive clinical data from our Phase 2 study, together with differentiated biomarker findings from our Phase 3 program reinforce our confidence in our pivotal Phase 3 study in metastatic breast cancer,\u201d stated William V. Williams, MD, BriaCell\u2019s President &amp; CEO. \u201cTogether with our pipeline of novel off-the-shelf cell-based immunotherapies, we remain committed to advancing breakthroughs in cancer immunotherapy as we work to improve survival and clinical outcomes in cancer patients with unmet medical needs.\u201d<\/p>\n<p align=\"justify\">\u201cOur biomarker data provides important insights into the mechanism of action of our novel immunotherapy with the goal of delivering more precisely targeted treatment options for oncologists, physicians, and patients,\u201d commented Miguel A. Lopez-Lago, PhD, BriaCell\u2019s Chief Scientific Officer.<\/p>\n<p align=\"justify\">\n        <strong>Late-Breaking Abstract Number:\u00a0<\/strong>3688<br \/><strong>Presentation Number: <\/strong>PS1-13-22<br \/><strong>Presentation Title:\u00a0<\/strong>Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial<br \/><strong>Poster Presentation Date\/Time: <\/strong>Wednesday, December 10, 2025, 12:30 PM &#8211; 2:00 PM CST<\/p>\n<p align=\"justify\">\n        <strong>Late-Breaking Abstract Number:\u00a0<\/strong>3713<br \/><strong>Presentation Number: <\/strong>PS1-13-23<br \/><strong>Presentation Title:\u00a0<\/strong>Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine<br \/><strong>Poster Presentation Date\/Time: <\/strong>Wednesday, December 10, 2025, 12:30 PM &#8211; 2:00 PM CST<\/p>\n<p align=\"justify\">\n        <strong>Abstract Number:<\/strong> 1614<br \/><strong>Presentation Number: <\/strong>PS2-09-03<br \/><strong>Presentation Title:<\/strong> Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.<br \/><strong>Poster Presentation Date\/Time: <\/strong>Wednesday, December 10, 2025, 5:00 PM &#8211; 6:30 PM CST<\/p>\n<p align=\"justify\">Copies of the abstracts and posters will be made available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6bbXAqmXSMi2w6zSMznhASngc8eucHWi3SbaV_uWXWY4mOVMtnuDE-c4g_wTrjwfGalUzyGRa2NtTfZq_MBwUVaT-aEvtaGoNX-Znr8STjFdv2aJUuzd-Qd02bj1GRBsGWveLGtHyXBwxhd54rdSPvk07rrFAgbU9jlensWlBzo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/scientific-publications\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6bbXAqmXSMi2w6zSMznhASngc8eucHWi3SbaV_uWXWZNl4FQaAoaCyCJyz7vA-zgvMXYJmvDqMk_Va76JFcTWNSQ36hQucJtMpJ97nQoMdk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three posters at the 2025 SABCS, and the contents of such posters, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ij_sVddj229Z6z_KLOIxThYc0zG4DTjAhlzmFC9aBhEHyenXqrNvXA1ks_E_bMt7WjUH55KrJ-PdDJKr7D5sor7F6eJCwxZ47c5Z8z43OAg=\" rel=\"nofollow\" target=\"_blank\"><strong><u>www.sedarplus.ca<\/u><\/strong><\/a>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ij_sVddj229Z6z_KLOIxTgAvlGBem98BvE3d6kj9Jg10Y7YDGWfjS6eXey93OJygnm8lLDfcHcl3e5WkaXfqKw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EZMwDPU2MtWFGBes_4hMwnoY5aEu8B9pEGOysLn9zphDdKx9oIqT_EaTlvOPVP6-C4X24nZQO2E-P1DHjsBf72SnbaPglziS8UdxHa6TOk8=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6R68YCNBy7JjFN1yJiigXQRi1zQSkqrxdUauJxK2e_meJWwtR48DAg99jZHZBAQcbzlO0-PmqkByxgrtHSA4Q3doKolH2x9ccfEJAXJIT6Q=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjI3YzQ4NzQtMDZhYy00MzdkLTljMzMtNTM5MzE1NWI4NWU5LTExMDIyMjktMjAyNS0xMS0yNS1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The pivotal Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026 The Bria-IMT regimen has received Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS\u00ae) taking place &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The pivotal Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026 The Bria-IMT regimen has received Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS\u00ae) taking place &hellip; Continue reading &quot;BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T12:35:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025\",\"datePublished\":\"2025-11-25T12:35:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/\"},\"wordCount\":703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/\",\"name\":\"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\",\"datePublished\":\"2025-11-25T12:35:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk","og_description":"Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The pivotal Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026 The Bria-IMT regimen has received Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS\u00ae) taking place &hellip; Continue reading \"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T12:35:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025","datePublished":"2025-11-25T12:35:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/"},"wordCount":703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/","name":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=","datePublished":"2025-11-25T12:35:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTc1NiM3MjkxMTg5IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-highlight-positive-phase-2-phase-3-clinical-data-at-sabcs-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell to Highlight Positive Phase 2 &amp; Phase 3 Clinical Data at SABCS\u00ae 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}